HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Laopu Gold (6181.HK) - Gold Stocks Are Different from Gold Commodities

Pre-IPO Banu International Holding - The Pain Points and the Outlook

Pre-IPO Jiangxi Institute of Biological Products-Concerns Behind the Strong Growth and Profitability

China TCM (570.HK) - Performance Is Expected to Rebound

Equity Capital Markets

Hangzhou Sciwind Biosciences / Equity Capital Markets

<ul>
<li>Competition in the entire GLP-1 market is constantly intensifying and evolving, which is expected to shift from the current focus solely on BMI indicators to a comprehensive patient-centered management model.</li>
<li>XW003 faces the challenge of head-to-head trials with competing drugs. There could be uncertainties in future clinical trials of XW004, XW014. Commercialization is a tough task for Sciwind’s GLP-1 pipeline.</li>
<li>The total peak sales of XW003, XW004 and XW014 could be RMB5-7 billion. Valuation of Sciwind could be lower than peers such as <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics (1801 HK), </a><a href="https://www.smartkarma.com/entities/guangzhou-innogen-pharmaceutical-group-co-ltd" target="_blank" data-smartkarma-citation="entities:44142:1" rel="noopener">Innogen (2591 HK).</a>  </li>
</ul>


Competition in the entire GLP-1 market is constantly intensifying and evolving, which is expected to shift from the current focus solely on BMI indicators to a comprehensive patient-centered management model.
XW003 faces the challenge of head-to-head trials with competing drugs. There could be uncertainties in future clinical trials of XW004, XW014. Commercialization is a tough task for Sciwind’s GLP-1 pipeline.
The total peak sales of XW003, XW004 and XW014 could be RMB5-7 billion. Valuation of Sciwind could be lower than peers such as Innovent Biologics (1801 HK), Innogen (2591 HK).  


Hangzhou Jiuyuan Gene Engineering (2566 HK)

Guangzhou Innogen Pharmaceutical Group (2591 HK)

Pre-IPO Hangzhou Sciwind Biosciences - Thoughts About the Industry and The GLP-1 Pipeline